These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 1466968)

  • 1. Design of a complete synthetic peptide-based AIDS vaccine with a built-in adjuvant.
    Nardelli B; Defoort JP; Huang W; Tam JP
    AIDS Res Hum Retroviruses; 1992 Aug; 8(8):1405-7. PubMed ID: 1466968
    [No Abstract]   [Full Text] [Related]  

  • 2. Induction of cross-reactive cytotoxic T-lymphocyte responses specific for HIV-1 gp120 using saponin adjuvant (QS-21) supplemented subunit vaccine formulations.
    Newman MJ; Wu JY; Gardner BH; Anderson CA; Kensil CR; Recchia J; Coughlin RT; Powell MF
    Vaccine; 1997 Jun; 15(9):1001-7. PubMed ID: 9261947
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficient CD8+ T cell response to the HIV-env V3 loop epitope from multiple virus isolates by a DNA prime/vaccinia virus boost (rWR and rMVA strains) immunization regime and enhancement by the cytokine IFN-gamma.
    Gómez CE; Abaitua F; Rodríguez D; Esteban M
    Virus Res; 2004 Sep; 105(1):11-22. PubMed ID: 15325077
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Studies on in vivo induction of HIV-1 envelope-specific cytotoxic T lymphocytes by synthetic peptides from the V3 loop region of HIV-1 IIIB gp 120.
    Nehete PN; Casement KS; Arlinghaus RB; Sastry KJ
    Cell Immunol; 1995 Feb; 160(2):217-23. PubMed ID: 7720083
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis of immunoadjuvant conjugates with HIV-derived peptide inducing peptide-specific antibody.
    Maruyama Y; Kurimura M; Achiwa K
    Chem Pharm Bull (Tokyo); 1994 Aug; 42(8):1709-11. PubMed ID: 7954925
    [No Abstract]   [Full Text] [Related]  

  • 6. Vaccination with HIV-1 gp120 DNA induces immune responses that are boosted by a recombinant gp120 protein subunit.
    Barnett SW; Rajasekar S; Legg H; Doe B; Fuller DH; Haynes JR; Walker CM; Steimer KS
    Vaccine; 1997 Jun; 15(8):869-73. PubMed ID: 9234536
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenicity of synthetic HIV-1 V3 loop peptides by MPL adjuvanted pH-sensitive liposomes.
    Chang JS; Choi MJ; Kim TY; Cho SY; Cheong HS
    Vaccine; 1999 Mar; 17(11-12):1540-8. PubMed ID: 10195791
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Polyvalent, recombinant HIV-1 virus-like particles: novel HIV-1 vaccine strategies.
    Wagner R; Deml L; Wolf H
    Antibiot Chemother (1971); 1994; 46():48-61. PubMed ID: 7826039
    [No Abstract]   [Full Text] [Related]  

  • 9. Development of HIV/AIDS vaccine using chimeric gag-env virus-like particles.
    Kang CY; Luo L; Wainberg MA; Li Y
    Biol Chem; 1999 Mar; 380(3):353-64. PubMed ID: 10223338
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhancement of HIV type 1 vaccine immunogenicity by block copolymer adjuvants. I. Induction of high-titer, long-lasting, cross-reactive antibodies of broad isotype.
    McNicholl JM; Bond KB; Ruhadze ER; Olsen MR; Takayama K; Hunter RL
    AIDS Res Hum Retroviruses; 1998 Nov; 14(16):1457-71. PubMed ID: 9824324
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of synthetic peptides in primates to induce high-titered neutralizing antibodies and MHC class I-restricted cytotoxic T cells against acquired immunodeficiency syndrome retroviruses: an HLA-based vaccine strategy.
    Haynes BF; Yasutomi Y; Torres JV; Gardner MB; Langlios AJ; Bolognesi DP; Matthews TJ; Scearce RM; Jones DM; Moody MA
    Trans Assoc Am Physicians; 1993; 106():33-41. PubMed ID: 8036743
    [No Abstract]   [Full Text] [Related]  

  • 12. Microparticles in MF59, a potent adjuvant combination for a recombinant protein vaccine against HIV-1.
    O'Hagan DT; Ugozzoli M; Barackman J; Singh M; Kazzaz J; Higgins K; Vancott TC; Ott G
    Vaccine; 2000 Mar; 18(17):1793-801. PubMed ID: 10699327
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased immunogenicity of HIV envelope subunit complexed with alpha2-macroglobulin when combined with monophosphoryl lipid A and GM-CSF.
    Liao HX; Cianciolo GJ; Staats HF; Scearce RM; Lapple DM; Stauffer SH; Thomasch JR; Pizzo SV; Montefiori DC; Hagen M; Eldridge J; Haynes BF
    Vaccine; 2002 May; 20(17-18):2396-403. PubMed ID: 12009296
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Production of a short recombinant C4V3 HIV-1 immunogen that induces strong anti-HIV responses by systemic and mucosal routes without the need of adjuvants.
    Varona-Santos JT; Vazquez-Padrón RI; Moreno-Fierros L
    Viral Immunol; 2006; 19(2):237-49. PubMed ID: 16817766
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Strong immunogenicity of a multicomponent peptide vaccine developed with the branched lysine oligopeptide method for human immunodeficiency virus infection.
    Okuda K; Kaneko T; Yamakawa T; Tanaka S; Shigematsu T; Yamamoto A; Hamajima K; Nakajima K; Kawamoto S; Phanuphak P
    J Mol Recognit; 1993 Sep; 6(3):101-9. PubMed ID: 8060667
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vaginal immunization of rats with a synthetic peptide from human immunodeficiency virus envelope glycoprotein.
    O'Hagan DT; Rafferty D; McKeating JA; Illum L
    J Gen Virol; 1992 Aug; 73 ( Pt 8)():2141-5. PubMed ID: 1645152
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adsorption to aluminum hydroxide promotes the activity of IL-12 as an adjuvant for antibody as well as type 1 cytokine responses to HIV-1 gp120.
    Jankovic D; Caspar P; Zweig M; Garcia-Moll M; Showalter SD; Vogel FR; Sher A
    J Immunol; 1997 Sep; 159(5):2409-17. PubMed ID: 9278332
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combinatorial peptide library as an immunogen.
    Estaquier J; Ameisen JC; Auriault C; Boutillon C; Gras-Masse H; Tartar A
    Methods Mol Biol; 1998; 87():281-96. PubMed ID: 9523278
    [No Abstract]   [Full Text] [Related]  

  • 19. Mucosal immunity to HIV-1: systemic and vaginal antibody responses after intranasal immunization with the HIV-1 C4/V3 peptide T1SP10 MN(A).
    Staats HF; Nichols WG; Palker TJ
    J Immunol; 1996 Jul; 157(1):462-72. PubMed ID: 8683152
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neutralization of HIV-1 by secretory IgA induced by oral immunization with a new macromolecular multicomponent peptide vaccine candidate.
    Bukawa H; Sekigawa K; Hamajima K; Fukushima J; Yamada Y; Kiyono H; Okuda K
    Nat Med; 1995 Jul; 1(7):681-5. PubMed ID: 7585151
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.